Literature DB >> 24224632

Survival in the prostate cancer prevention trial.

Catherine M Tangen, Phyllis J Goodman, Ian M Thompson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24224632      PMCID： PMC4927191          DOI： 10.1056/NEJMc1311498

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  4 in total

1.  The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention.

Authors:  Marc R Theoret; Yang-Min Ning; Jenny J Zhang; Robert Justice; Patricia Keegan; Richard Pazdur
Journal:  N Engl J Med       Date:  2011-06-15       Impact factor: 91.245

2.  Projecting prostate cancer mortality in the PCPT and REDUCE chemoprevention trials.

Authors:  Paul F Pinsky; Amanda Black; Robert Grubb; E David Crawford; Gerald Andriole; Ian Thompson; Howard Parnes
Journal:  Cancer       Date:  2012-08-14       Impact factor: 6.860

3.  Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach.

Authors:  Mary W Redman; Catherine M Tangen; Phyllis J Goodman; M Scott Lucia; Charles A Coltman; Ian M Thompson
Journal:  Cancer Prev Res (Phila)       Date:  2008-05-18

4.  Long-term survival of participants in the prostate cancer prevention trial.

Authors:  Ian M Thompson; Phyllis J Goodman; Catherine M Tangen; Howard L Parnes; Lori M Minasian; Paul A Godley; M Scott Lucia; Leslie G Ford
Journal:  N Engl J Med       Date:  2013-08-15       Impact factor: 91.245
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.